[{"from": "human", "value": "Provide a description of this molecule. [C][C][=C][C][=Branch2][Branch1][P][=C][C][=Branch2][Branch1][O][=C][Ring1][=Branch1][C][C@@H1][Branch2][Branch1][C][C][=Branch1][C][=O][N][Branch2][Ring1][Branch1][C][C][=C][C][=Branch1][#Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][=Branch1][C][=O][O][C@@H1][Branch1][C][C][C][=N][C][=C][Branch1][Ring2][N][Ring1][Branch1][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C][C][=Branch1][C][=O][N]"}, {"from": "gpt", "value": "The molecule is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D.   Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces \ufb02uid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale."}]